# A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma

Source: https://onco.cc/trials/nct07452198/  
OnCo record `nct07452198` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial testing GR1803 in multiple myeloma, now recruiting.

## Summary

A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma is a phase 3 interventional study registered as NCT07452198, led by Genrix (Shanghai) Biopharmaceutical, and recruiting on the registry. Official title: A Phase 3, Multicenter, Open-Label, Randomised Study Comparing GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma Who Have Received 1 to 3 Prior Lines of Therapy Including Lenalidomide and Proteasome Inhibitors. Planned enrolment is 358 participants (estimated). The study started in 2026-03-09 and primary completion is expected in 2029-03. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-11
- Tags: ctgov-ingest
- Registry id: NCT07452198
- Phase: 3
- Setting: A Phase 3, Multicenter, Open-Label, Randomized Study Comparing GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma Who Have Received 1 to 3 Prior Lines of Therapy Including Lenalidomide and Proteasome Inhibitors
- Sponsor: Genrix (Shanghai) Biopharmaceutical
- Enrolled: 358

## Sources

- ClinicalTrials.gov NCT07452198: https://clinicaltrials.gov/study/NCT07452198

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/), [Relapsed or refractory multiple myeloma](https://onco.cc/cancers/myeloma-relapsed-refractory/)
- drugs: [GR1803](https://onco.cc/drugs/gr1803/)
- companies: [Genrix Bio](https://onco.cc/companies/genrix-bio/)

---
JSON: https://onco.cc/api/v1/entities/nct07452198.json